PEG-L-CHOP treatment is safe and effective in adult extranodal NK/T-cell lymphoma with a low rate of clinical hypersensitivity

Autor: Xiaopei Wang, Wen Zheng, Yuhuan Gao, Chen Zhang, Lingyan Ping, Weiping Liu, Hanyun Ren, Liping Su, Yan Xie, Lijuan Deng, Meifeng Tu, Jun Zhu, Ningjing Lin, Xiaoyan Ke, Zhitao Ying, Weijing Zhang, Yuqin Song
Jazyk: angličtina
Rok vydání: 2018
Předmět:
Male
0301 basic medicine
Oncology
Cancer Research
CHOP
Polyethylene Glycols
PEG-ASP)
0302 clinical medicine
Antineoplastic Combined Chemotherapy Protocols
T-cell lymphoma
Neoplasm Metastasis
Middle Aged
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Lymphoma
Extranodal NK-T-Cell
Clinical trial
Treatment Outcome
Bone marrow suppression
Vincristine
030220 oncology & carcinogenesis
Female
Polyethylene glycol-conjugated asparaginase (pegaspargase
medicine.drug
Adult
medicine.medical_specialty
Cyclophosphamide
Extranodal natural killer (NK)/T-cell lymphoma (NKTCL)
lcsh:RC254-282
03 medical and health sciences
Internal medicine
Genetics
medicine
Asparaginase
Humans
Survival rate
Aged
Neoplasm Staging
business.industry
medicine.disease
Regimen
030104 developmental biology
Doxorubicin
Drug Resistance
Neoplasm
Prednisone
Therapy
business
Biomarkers
Follow-Up Studies
Zdroj: BMC Cancer, Vol 18, Iss 1, Pp 1-9 (2018)
ISSN: 1471-2407
DOI: 10.1186/s12885-018-4782-y
Popis: The combination of chemotherapy and L-asparaginase (L-ASP) treatment significantly increased survival rate in an adult patient with extranodal natural killer (NK)/T-cell lymphoma (NKTCL). However, hypersensitivity reactions of L-ASP in some patients limited its application. Polyethylene glycol-conjugated asparaginase (PEG-ASP) has a lower immunogenicity and longer circulating half-life than unconjugated L-ASP, and has been reported to be effective and well-tolerated in children with acute lymphoblastic leukemia. Cyclophosphamide, hydroxydaunorubicin (doxorubicin), oncovin (vincristine), and prednisolone (CHOP) is the most common chemotherapy for non-Hodgkin lymphoma. In this report, we sought to study the efficacy and safety of PEG-L- CHOP in NKTCL in adult Chinese patients. Our study is a prospective, multi-center, open-label clinical trial. Patients with newly diagnosed adult NKTCL and an ECOG performance status of 0 to 2 were eligible for enrollment. Treatment included six cycles of PEG-L-CHOP regimen. Radiotherapy was scheduled after 2–4 cycles of PEG-L-CHOP regimen, depending on the stage and primary anatomic site. We enrolled a total of 33 eligible patients. All 33 patients completed 170 cycles of chemotherapy combined with radical radiotherapy. The overall response rate was 96.9% (32/33) with 75.8% (25/33) achieving complete responses and 21.2% (7/33) achieving partial responses. The overall survival (OS) at 1, 2, 3-year were 100, 90.61 and 80.54%, respectively. The major adverse effects were bone marrow suppression, reduction of fibrinogen level, liver dysfunction, and digestive tract toxicities. No allergic reaction and no treatment-related mortality or severe complications were recorded. PEG-L-CHOP chemotherapy in combination radiotherapy is safe and durably effective treatment for adult extranodal NK/T-cell lymphoma with fewer allergic reactions. This study was approved by the Peking University Beijing Cancer Hospital Ethics Review Committee (reference number: 2011101104). The clinical trial registration number ChiCTR1800016940 was registered on July 07, 2018 at the Chinese Clinical Trial Registry ( http://www.chictr.org.cn/index.aspx ). The clinical trial was registered retrospectively.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje